D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC ...

Morgan Stanley analyst Judah Frommer maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target ...